Neonc Technologies Holdings Inc (NTHI)

$12.00 -0.11 (-0.91%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 9,700
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and s...

Industry: Biotechnology
Sector: Healthcare
Phone: 310-663-7831
Address:
23975 Park Sorrento, Suite 205, Calabasas, United States
DavidFarnsworth669
DavidFarnsworth669 Dec. 25 at 2:32 PM
$VST $RUN $IMRX $NTHI Major players entering the market
0 · Reply
CarolMorse3
CarolMorse3 Dec. 25 at 12:43 PM
$VST $RUN $IMRX $NTHI '
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Dec. 25 at 11:54 AM
$NTHI “The consistency and durability of these responses continue to exceed expectations. With radiographic responses now 300% higher than historically reported salvage therapies, these data reinforce our conviction that NEO100 may represent a meaningful advance for patients with recurrent IDH1-mutant gliomas.” - Amir F. Heshmatpour, Executive Chairman, President & CEO, NeOnc Technologies Independent experts have described the results as a potential paradigm shift in this hard-to-treat disease. #NeOnc #NTHI #BiotechNews #CNS #CancerResearch #LongTermSurvival #IR
0 · Reply
InductionInv
InductionInv Dec. 25 at 9:42 AM
$NTHI Forward momentum is increasingly dictated by operational clarity, because growth without leverage now attracts skepticism. Clear follow‑through could unlock sustainable re‑rating.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Dec. 24 at 11:36 AM
$NTHI Our recent news on intranasal NEO100 is highly encouraging - updated results from NeOnc’s Phase 1/2a and compassionate-use experience show: • 24% radiographic remission (6/25 patients) • 44% PFS-6, vs. 21–31% historical benchmarks • 36% alive ≥18 months post-treatment • No significant toxicity with chronic dosing These outcomes exceed typical salvage therapy results and reinforce the durability and reproducibility of NEO100’s clinical signal. #NTHI #BiotechStocks #ClinicalData #BrainTumor #IDH1 #Investing #Healthcare
0 · Reply
BlueSkyBuyer
BlueSkyBuyer Dec. 24 at 10:19 AM
$NTHI Market attention is shifting toward whether execution velocity aligns with stated operational milestones. Execution slippage remains the dominant downside risk.
0 · Reply
DARKP00L
DARKP00L Dec. 23 at 10:25 PM
$NTHI 17:10 on Dec. 23 2025 NeOnc Technologies Files Prospectus For Offer & Sale From Time To Time By Selling Stockholders For Up To 111,732 Shares Of Common Stock #tradeideas
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Dec. 23 at 9:49 AM
$NTHI New Podcast with Amir Heshmatpour, CEO of NeOnc Technologies 🚨 We’re excited to share insights straight from NeOnc’s leadership on their Phase 2 brain cancer program: ~300% improved efficacy vs. the current standard of care Key readout expected in ~6 months 179 global patents addressing a $4B market No jargon. No gatekeepers. Just a discussion on the potential upside and the future of NeOnc’s innovative therapies. Watch the full conversation here: https://x.com/LouBasenese/status/2001656633005396181 #NeOnc #BrainCancer #Innovation #Biotech #InvestorRelations
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 5:37 AM
$NTHI RSI: 42.02, MACD: -0.3157 Vol: 0.91, MA20: 8.72, MA50: 9.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 5:00 AM
$NTHI RSI: 42.02, MACD: -0.3157 Vol: 0.91, MA20: 8.72, MA50: 9.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on NTHI
NeOnc Technologies Reports Updated Clinical Results

Dec 15, 2025, 9:00 AM EST - 10 days ago

NeOnc Technologies Reports Updated Clinical Results

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

Dec 1, 2025, 9:00 AM EST - 24 days ago

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

Nov 13, 2025, 9:00 AM EST - 6 weeks ago

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

Nov 7, 2025, 9:00 AM EST - 6 weeks ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

NeOnc Technologies: From Survival Mode To Expansion Mode

Oct 9, 2025, 2:25 PM EDT - 2 months ago

NeOnc Technologies: From Survival Mode To Expansion Mode

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

Oct 9, 2025, 9:00 AM EDT - 2 months ago

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Sep 29, 2025, 9:00 AM EDT - 3 months ago

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

Sep 10, 2025, 9:40 AM EDT - 3 months ago

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

BGL

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

Sep 10, 2025, 9:00 AM EDT - 3 months ago

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

Aug 25, 2025, 9:00 AM EDT - 4 months ago

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

Aug 11, 2025, 9:00 AM EDT - 4 months ago

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

Aug 7, 2025, 9:00 AM EDT - 5 months ago

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

Aug 4, 2025, 9:00 AM EDT - 5 months ago

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

Jul 30, 2025, 9:00 AM EDT - 5 months ago

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

Jul 23, 2025, 10:53 AM EDT - 5 months ago

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

Jul 8, 2025, 9:00 AM EDT - 6 months ago

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

Jun 6, 2025, 9:00 AM EDT - 7 months ago

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

Apr 15, 2025, 8:05 AM EDT - 9 months ago

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

Apr 14, 2025, 8:05 AM EDT - 9 months ago

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

Apr 10, 2025, 8:05 AM EDT - 9 months ago

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

Apr 8, 2025, 4:05 PM EDT - 9 months ago

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Mar 31, 2025, 8:05 AM EDT - 9 months ago

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

Mar 27, 2025, 8:05 AM EDT - 9 months ago

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

Mar 25, 2025, 8:45 AM EDT - 9 months ago

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

Mar 25, 2025, 8:15 AM EDT - 9 months ago

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

Jan 4, 2025, 12:30 AM EST - 1 year ago

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

AERO CAPS CRGT FBGL FLOC INLF INR

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

Oct 7, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

Aug 5, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

Jul 16, 2024, 11:15 AM EDT - 1 year ago

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

Jun 26, 2024, 4:39 PM EDT - 1 year ago

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

May 15, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

May 9, 2024, 5:30 PM EDT - 1 year ago

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

Mar 30, 2024, 1:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

BOLD MMA MNDR NTCL ROTR UBXG WAY

U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline

Dec 25, 2023, 9:05 AM EST - 2 years ago

U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline

LGCB MAMO LZMH

Neonc Technologies Seeks U.S. IPO For Brain Cancer Treatment Pipeline

Dec 20, 2023, 2:38 PM EST - 2 years ago

Neonc Technologies Seeks U.S. IPO For Brain Cancer Treatment Pipeline

DavidFarnsworth669
DavidFarnsworth669 Dec. 25 at 2:32 PM
$VST $RUN $IMRX $NTHI Major players entering the market
0 · Reply
CarolMorse3
CarolMorse3 Dec. 25 at 12:43 PM
$VST $RUN $IMRX $NTHI '
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Dec. 25 at 11:54 AM
$NTHI “The consistency and durability of these responses continue to exceed expectations. With radiographic responses now 300% higher than historically reported salvage therapies, these data reinforce our conviction that NEO100 may represent a meaningful advance for patients with recurrent IDH1-mutant gliomas.” - Amir F. Heshmatpour, Executive Chairman, President & CEO, NeOnc Technologies Independent experts have described the results as a potential paradigm shift in this hard-to-treat disease. #NeOnc #NTHI #BiotechNews #CNS #CancerResearch #LongTermSurvival #IR
0 · Reply
InductionInv
InductionInv Dec. 25 at 9:42 AM
$NTHI Forward momentum is increasingly dictated by operational clarity, because growth without leverage now attracts skepticism. Clear follow‑through could unlock sustainable re‑rating.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Dec. 24 at 11:36 AM
$NTHI Our recent news on intranasal NEO100 is highly encouraging - updated results from NeOnc’s Phase 1/2a and compassionate-use experience show: • 24% radiographic remission (6/25 patients) • 44% PFS-6, vs. 21–31% historical benchmarks • 36% alive ≥18 months post-treatment • No significant toxicity with chronic dosing These outcomes exceed typical salvage therapy results and reinforce the durability and reproducibility of NEO100’s clinical signal. #NTHI #BiotechStocks #ClinicalData #BrainTumor #IDH1 #Investing #Healthcare
0 · Reply
BlueSkyBuyer
BlueSkyBuyer Dec. 24 at 10:19 AM
$NTHI Market attention is shifting toward whether execution velocity aligns with stated operational milestones. Execution slippage remains the dominant downside risk.
0 · Reply
DARKP00L
DARKP00L Dec. 23 at 10:25 PM
$NTHI 17:10 on Dec. 23 2025 NeOnc Technologies Files Prospectus For Offer & Sale From Time To Time By Selling Stockholders For Up To 111,732 Shares Of Common Stock #tradeideas
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Dec. 23 at 9:49 AM
$NTHI New Podcast with Amir Heshmatpour, CEO of NeOnc Technologies 🚨 We’re excited to share insights straight from NeOnc’s leadership on their Phase 2 brain cancer program: ~300% improved efficacy vs. the current standard of care Key readout expected in ~6 months 179 global patents addressing a $4B market No jargon. No gatekeepers. Just a discussion on the potential upside and the future of NeOnc’s innovative therapies. Watch the full conversation here: https://x.com/LouBasenese/status/2001656633005396181 #NeOnc #BrainCancer #Innovation #Biotech #InvestorRelations
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 5:37 AM
$NTHI RSI: 42.02, MACD: -0.3157 Vol: 0.91, MA20: 8.72, MA50: 9.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 5:00 AM
$NTHI RSI: 42.02, MACD: -0.3157 Vol: 0.91, MA20: 8.72, MA50: 9.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Dec. 22 at 9:24 AM
$NTHI NeOnc Reports Expanded Long-Term Survival in Recurrent Brain Cancer NeOnc Technologies (Nasdaq: NTHI) announced updated clinical data for intranasal NEO100 in recurrent Grade III/IV IDH1-mutant astrocytoma. An additional patient has now achieved durable long-term survival and radiographic remission, strengthening an already compelling clinical signal across a 25-patient cohort. With no significant toxicity observed, these results continue to support NEO100’s potential as a meaningful advance in neuro-oncology. https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-reports-updated-clinical-results-0
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 19 at 11:15 PM
$NTHI
0 · Reply
quodo
quodo Dec. 15 at 2:25 PM
$SMTI $CMMB $SERA $NTHI Most small caps are still trying to survive 2026. $CAPS is already planning how to compound through it. $100M run-rate reaffirmed. Margins expanding. Execution > speculation.
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 15 at 2:01 PM
$NTHI NeOnc Technologies Reports Updated Clinical Results
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Dec. 9 at 12:28 PM
$NTHI “This breakthrough provides strong external validation for NEO100’s potential as a first-in-class, noninvasive sonodynamic therapeutic. The integration of AI, 3D bioprinting, and ultrasound significantly expands NEO100’s commercial and clinical opportunity beyond current indications,” said Amir Heshmatpour, CEO, Executive Chairman, and President of NTHI.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Dec. 8 at 2:11 PM
$NTHI We recently announced significant AI-driven findings demonstrating that focused ultrasound further amplifies the therapeutic potency of NEO100 across both primary and metastatic brain tumors. This breakthrough positions NeOnc Technologies at the forefront of next-generation, noninvasive sonodynamic therapy. https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-nasdaq-nthi-announces-ai-driven-findings
0 · Reply
topstockalerts
topstockalerts Dec. 5 at 1:56 PM
Pre Market Top Gainers PT2 $AKAN $NTHI $SNSE $ARBKL $IRBT
0 · Reply
topstockalerts
topstockalerts Dec. 5 at 1:00 PM
Pre Market Top Gainers PT2 $NTHI $QCLS $STIM $AMCI $LGHL
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Dec. 4 at 10:35 AM
$NTHI We at NeOnc Technologies (Nasdaq: NTHI) are extremely proud to announce newly published preclinical findings from a research collaboration at the University of Southern California (USC). The study, now available on bioRxiv (https://www.biorxiv.org/content/10.1101/2025.11.25.690556v1), demonstrates that ultrasound further enhances and amplifies NEO100’s therapeutic potency, driving strong antitumor effects across multiple primary and metastatic brain tumor types. Read more about this milestone here: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-nasdaq-nthi-announces-ai-driven-findings
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 1 at 2:00 PM
$NTHI NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 26 at 1:22 PM
$NTHI Amir Heshmatpour on recent completion of enrollment in pivotal NEO100 Phase 2a trial for IDH-1 mutant recurrent high-grade glioma and expectation of interim data readout in Q2 2026: “Having now completed full enrollment, we can comprehensively assess NEO100’s impact across a complete patient population. The strength of the data observed to date reinforces our confidence that our proprietary intranasal delivery platform — uniquely designed to bypass the blood-brain barrier represents a breakthrough approach for treating aggressive brain tumors. We believe these data will not only strengthen our clinical position but also strategically advance NeOnc toward becoming a global leader in CNS oncology innovation, with a first-mover advantage and a defensible moat protecting our extensive intellectual property portfolio.”
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 26 at 5:29 AM
$NTHI NeOnc Technologies Holdings Inc. (OTC:NTHI) delivered a major breakthrough in CNS oncology with NEO100 showing a 21 percent response rate versus less than 8 percent historically, 44 percent six-month PFS, and 33 percent eighteen-month survival in recurrent high-grade gliomas. As NTHI advances toward a May 2026 top-line readout and a $50 million Middle East partnership, investor interest is surging. https://biotechhealthx.com/biotech-news/neonc-technologies-nthi-stuns-wall-street-with-breakthrough-21-response-rate-in-brain-cancer-trial/
0 · Reply